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Mesenchymal stem cells (MSCs) have both stemness and multi-modulatory activities
on other cells, and the immunosuppressive and tumor-promotive mechanisms have
been intensively investigated in cancer. The role of MSCs appears to be revealed in
tumor aggravation, and targeting MSCs seems to be a promising strategy for treating
cancer patients. However, it is still impractical in clinical therapy, since the precise
MSCs are poorly understood in the in vivo setting. In previous studies, MSCs were
obtained from different sources, and were prepared by ex vivo expansion for a long
term. The inconsistent experimental conditions made the in vivo MSCs obscure. To
define the MSCs in the host is a priority issue for targeting MSCs in cancer therapy.
We recently identified a unique subpopulation of MSCs increasing in mice and human
with cancer metastasis. These MSCs are specifically expanded by metastatic tumor
cells, and promote tumor progression and dissemination accompanied by immune
suppression and dysfunction in the host, more powerfully than normal MSCs growing
without interference of cancer. In this review, we summarize current knowledge of the
role of MSCs in tumor aggravation, along with our new findings of the bizarre MSCs.
Keywords: mesenchymal stem cell, cancer, metastasis, epithelial-to-mesenchymal transition,
immunosuppression
Introduction
Mesenchymal stem cells (MSCs) have stemness including self-renewability and pluripotency to dif-
ferentiate into adipocytes, osteocytes, chondrocytes, fibroblasts, pericytes and more, and also have
multiple immunoregulatory properties for maintaining immune tolerance (Uccelli et al., 2008;
Liu et al., 2009). MSCs suppress immune responses directly by producing immunomodulatory
molecules such as IDO, PGE2, TGFβ and nitric oxide, and indirectly via generation and expansion
of potent immunosuppressors such as CD4+FOXP3+ or CD8+FOXP3+ regulatory T cells (Tregs)
and myeloid-derived regulatory cells including dendritic cells (DCregs), monocytes/macrophages
(M-MDSCs) and granulocytes (G-MDSCs) (Nauta and Fibbe, 2007; Uccelli et al., 2008; Mag-
gini et al., 2010). Recent studies have demonstrated that MSCs are originally silent, and become
immunosuppressive by activation with pro-inflammatory cytokines such as IFNγ, TNFα, and IL-
1β, and ligation of TLRs such as TLR2, TLR3, and TLR4 expressed on the MSCs (Burr et al., 2013;
English, 2013). This suggests that the functional role of MSCs depends on the components within
the microenvironment.
Tumor tissues contain a number of influential factors for recruiting and activatingMSCs (Uccelli
et al., 2008; Yang et al., 2013). In turn, in the tumor microenvironment, the MSCs modulate
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biological properties of tumor cells directly by causing epithelial-
to-mesenchymal transition (EMT) followed by induction of
tumor metastasis and cancer-initiating stem cells (CSCs), and
indirectly via angiogenesis followed by promotion of tumor
growth (Uccelli et al., 2008; Yang et al., 2013). These totally lead
to tumor heterogeneity responsible for resistance to various treat-
ments. Thus, targeting immunoregulatory and tumor-promotive
MSCs seems to be a promising strategy for both attenuating the
tumor malignancy, and improving the host immunity against
cancer in treating patients.
However, targeting MSCs is still unrealistic in clinical settings,
because the in vivo MSC profiles remain obscure. The surface
molecules expressed in MSCs have been widely investigated, and
many studies demonstrated the high expression of CD49a, CD73,
CD90, CD105, CD146, CD271, and STRO-1, but not CD11b,
CD14, CD19, CD34, CD45, CD79a in human MSCs (Nauta and
Fibbe, 2007; Kuhn and Tuan, 2010). However, these molecules
are not unique markers specific for MSC phenotype and func-
tion. In previous studies, MSCs were mostly obtained from dif-
ferent sources followed by ex vivo expansion for a long term.
This implies that only a part of MSC subpopulations might be
selectively expanded, or transformation in MSCs might gener-
ate another type different from the original MSCs in the host.
Furthermore, the biological properties of MSCs may be much
moremodulated under cancer thanwe have ever known in regen-
erative research without cancer. These inconsistent experimen-
tal conditions impede development of targeting MSCs in cancer
therapy. To rigorously define the precise MSCs in cancer patients
is a priority issue for the practical application of MSC targeting in
the treatment.
We have been exploring novel anticancer therapeutics by
focusing on the interplay between neoplastic lesions and host
immunity for a while, and have recently provided new insights
into the metastatic process (Kudo-Saito, 2013; Kudo-Saito et al.,
2013a, 2014). Using murine and human tumor cells with typ-
ical features of EMT, high motility and invasivity, following
transduction of a cDNA coding for snail family zinc finger 1
(Snail), we found that Snail+ metastatic tumor cells specifically
release a large amount of TSP1 (Kudo-Saito et al., 2009), CCL2
(Kudo-Saito et al., 2013b), and FSTL1 (Kudo-Saito, 2013; Kudo-
Saito et al., 2013a), all of which can generate immune sup-
pression and dysfunction mediated by immunoregulatory cells
including CD4+Foxp3+ Tregs, CD11c+MHC IIlow/− DCregs
and CD45−ALCAM+ MSCs, and functionally impaired CD8low
T cells. This pathway totally accelerates cancer metastasis in the
host. Among the Snail+ tumor-producing factors, FSTL1, which
is a member of the SPARC family (Sylva et al., 2013), is an out-
standing molecule playing a dual role in cancer metastasis par-
ticularly to the bones. FSTL1 confers the invasive potential and
bone tropism on tumor cells, and also generates and expands
CD45−ALCAM+ MSCs initially in bone marrow and sequen-
tially all over the body in the host (Kudo-Saito, 2013; Kudo-Saito
et al., 2013a). We compared the biological properties between
Snail/FSTL1-expanded MSCs (designated “sMSCs”) and other
MSCs manipulated by none or non-metastatic tumor cells pre-
pared in vitro and in vivo. The in vitro MSCs were CD45− cells
sorted from bone marrow, spleen and peripheral blood of naive
mice followed by stimulation with none or culture supernatant of
Snail− or Snail+ tumor cells for 5–7 days. The in vivoMSCs were
CD45− cells freshly isolated from those tissues of naive mice or
the mice implanted with Snail− or Snail+ tumor cells (labeled
with GFP for elimination). We found that the sMSCs prepared
either in vitro or in vivo specifically produce ANGPT2, CCL2,
CCL3, and FSTL1, and most powerfully affect tumor behavior
and host immunity by using these molecules (unpublished data
except CCL2). ALCAM is expressed only in these MSCs, but not
in normal MSCs growing without interference of cancer. These
MSCs could be the “activated MSCs” with immunoregulatory
properties, since ALCAM is known as an activation marker as
well as a MSC marker (Weidle et al., 2010). We validated these
results observed in the murine system, using human system with
human tumor cells and PBMCs. In addition, we immunohis-
tochemically analyzed tumor tissues of advanced breast cancer
patients, and found that accumulation of ALCAM+ cells (pos-
sibly including the sMSCs) significantly correlates with FSTL1
expression level in tumor portions, but not in the adjacent nor-
mal counterparts. This points to the in vivo existence of a causal
molecular connection between FSTL1 and ALCAM within the
tumor microenvironment in patients.
In another study focusing on human endogenous retrovirus
antigen H (HERV-H) that is frequently and highly expressed
in metastatic tumor cells, we also found that CD45−CD271+
MSCs are specifically recruited by CCL19 released from HERV-
H+ tumor cells in the microenvironment (Kudo-Saito et al.,
2014). These MSCs are expanded by a 17-mer peptide that is
encoded in the immunosuppressive domain of the HERV-H
envelope protein. HERV-H was also found to upstreamly reg-
ulate Snail and Twist expressions in the metastatic tumor cells.
In the immunohistochemical analysis, the significant correlation
between HERV-H and CCL19 expressions and accumulation of
CD271+ cells (possibly including the HERV-H-induced MSCs)
was observed in tumor tissues of colon cancer patients. This also
suggests the clinical relevance of the experimental findings. Later,
we additionally found a high similarity of the phenotype and
function between the sMSCs and the HERV-H-induced MSCs.
Both ALCAM and CD271 are the functional molecules required
for cell proliferation and sphere formation of theseMSCs, and the
soluble factors released by the sMSCs are also upregulated in the
HERV-H-induced MSCs (unpublished data). This suggests that
the CD45−ALCAM+CD271+ MSCs (also designated “sMSCs”
below) could be the cancer-activated MSCs in vivo, particularly
generated and expanded in the presence of cancer metastasis in
patients. The sMSCs would be a promising target for breaking
through the difficulty in treating patients with cancer metasta-
sis and impaired immunity. Here, we summarize the current
knowledge of the diversified functional role of the bizarre sMSCs
(Figure 1) including normal MSCs in tumor aggravation.
MSCs Promote Tumor Growth
Because of the high migratory property, MSCs promptly migrate
into tumor tissues in response to the inflammatory molecules
including chemokines such as CCL5 (Karnoub et al., 2007;
Luo et al., 2014) and CXCL16 (Jung et al., 2013). MSCs were
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FIGURE 1 | Tumor aggravation caused by the sMSCs. When EMT
happens in tumor cells, the Snail+ metastatic tumor cells generate
and expand multifunctional sMSCs that highly release FSTL1, CCL2,
CCL3, and ANGPT2 for potentiating tumor aggravation. The sMSCs
promote tumor progression and metastasis by building tumor
heterogeneity within the microenvironment, and induce immune
suppression and dysfunction for further accelerating the tumor survival
and escape.
considered to contribute to tumor progression by causing angio-
genesis essential for tumor survival and growth after differentia-
tion into the cancer-associated cells such as fibroblasts (CAFs),
pericytes and endothelial cells (Bergfeld and Declerck, 2010).
However, the role of the MSC itself begins to be recognized
in tumor progression. One paper has demonstrated that CD44
expressed in MSCs is a functional molecule crucial for the
migratory and angiogenic properties of the differentiated CAFs
(Spaeth et al., 2013). This suggests that the functional role of
fibroblasts depend on the original MSCs. In our study, a num-
ber of angiogenic factors were significantly upregulated in the
sMSCs, and also in the MSCs manipulated by non-metastatic
tumor cells as compared to normal MSCs. This seems to be
the cancer-associated features. Particularly, ANGPT2 and CCL2
were specifically released by the sMSCs leading to the muchmore
aggressive tumor growth, although no superior production of
other potent angiogenic molecules like VEGFs was seen in the
sMSCs compared to other MSCs (unpublished data). When the
sMSCs were transfected with siRNAs specific for angpt2 or ccl2
before coinjection with tumor cells in mice, the sMSC-induced
tumor growth accompanied by increase of F4/80+TIE2+ tumor-
associated macrophages (TAMs) or CD11b+Gr1+ MDSCs in the
tumor tissues was significantly inhibited. This suggests that the
sMSC-derived ANGPT2 and CCL2 play a key role in the sMSC-
induced tumor growth. ANGPT2, which binds to TEK/TIE2, is
the antagonist of a potent angiogenic molecule ANGPT1 (Fagiani
and Christofori, 2013). However, as well as CCL2, ANGPT2
has been demonstrated to promote tumor growth indirectly via
increase of TIE2+ TAM-like macrophages in the tumor microen-
vironment (De Palma and Naldini, 2011). FSTL1 was reported to
significantly increase in CAFs within stroma of colon cancer tis-
sues (Torres et al., 2013). However, FSTL1 was a small impact on
tumor growth in our study.
Some studies have reported noMSC efficacy on tumor growth
(Bergfeld and Declerck, 2010). One possible reason for the para-
doxical effects may be the experimental conditions such as MSC
sources and in vitro culture term. Another possible reason may
be the distribution site and the amount of the MSCs in vivo. In
our experiments, the sMSC effect on tumor growth depended on
the route of injection of MSCs into mice. Subcutaneous tumor
growth was much more aggressively promoted by subcutaneous
(s.c.) coinjection with the sMSCs as compared to the case of
intravenous (i.v.) injection, by which only a small and limited
amount of the sMSCs spontaneously migrated into the tumor
tissues (Kudo-Saito et al., 2013a).
MSCs Promote Tumor Metastasis
Recent studies begin to uncover the roles of MSCs in facilitat-
ing tumor metastasis. CCL5 is one of the chemokines produced
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from both tumor cells and MSCs in the tumor tissues of breast
cancer (Karnoub et al., 2007) and prostate cancer (Luo et al.,
2014). Tumor-derived CCL5 recruits MSCs to the microenvi-
ronment, and the MSCs also release CCL5 for inducing EMT in
the tumor cells. Possibly because the major source of MSCs is
bone marrow, the relationship between MSCs and bone metas-
tasis has been intensively investigated (Bergfeld and Declerck,
2010). Bone metastasis is frequently seen in patients, particularly
with breast cancers and prostate cancers, giving a high risk that
deteriorates the quality of life of patients leading to poor prog-
nosis (Weilbaecher et al., 2011). Previous studies demonstrated
that tumor cells migrate into bone marrow in response to vari-
ous chemokines and cytokines such as CXCL12, CCL2, and IL6,
which are released by MSCs (Bergfeld and Declerck, 2010). How-
ever, little is known about the molecular mechanisms how MSCs
direct tumor cells to the bone.
In our study, we did not observed the significant produc-
tion of CCL5 and CXCL12 in the sMSCs. Instead, ANGPT2,
CCL2, and FSTL1 are significantly upregulated in the sMSCs
compared to other MSCs (Kudo-Saito et al., 2013a). The cru-
cial roles of ANGPT2 (Minami et al., 2013; Rigamonti and De
Palma, 2013) and CCL2 (Lu et al., 2009; Tang and Tsai, 2012)
have been already established in the mechanism of cancer metas-
tasis. We also demonstrated the significance of CCL2 in EMT-
associated cancer metastasis (Kudo-Saito et al., 2013b). Later, we
additionally found that FSTL1 plays a key role in bone metas-
tasis. FSTL1 can confer bone polarity on tumor cells by induc-
ing the bone metastasis-associated molecular expression such as
CCR2, CXCR4, and RANKL (Kudo-Saito et al., 2013a). Cancer
metastasis is amplified by CCL2 and FSTL1, which are abun-
dantly produced by both the sMSCs and the metastatic tumor
cells within the tumor microenvironment. Interestingly, in addi-
tion to the soluble factors, cell-cell contact between tumor cells
and the sMSCs is required for tumor metastasis, particularly to
bone marrow, where is a niche for maintaining CSCs (Kudo-
Saito et al., 2013a). This is also involved in the mechanism of the
sMSC-created tumor heterogeneity as described below.
MSCs Create Tumor Heterogeneity and
Complexity
It is increasingly being recognized that every tumor cell has a dif-
ferent profile in gene expression and cellular function even if the
source (tumor tissue and patient) is just same, and the clonal evo-
lution in a tumor cell builds tumor heterogeneity and complexity
governing resistance to the treatments leading to poor outcome
in patients (Junttila and De Sauvage, 2013). Although the extra-
cellular matrix is one of the most influential factors for altering
tumor properties (Faurobert et al., 2015), MSCs have been also
demonstrated to play a key role in generating CSCs with a high
metastaticity, dormancy and chemoresistance. In our study, we
also observed that tumor cells transform into CSC-like tumor
cells following in vitro coculture or in vivo coinjection with the
sMSCs (Kudo-Saito et al., 2013a). This is partly mediated by cell-
cell interaction through the ALCAM-ALCAM homophilic bind-
ing after ALCAM clustering on the cell surface, which is crucial
for proliferation and colonization of CSCs (Weidle et al., 2010)
and the sMSCs (Kudo-Saito et al., 2013a). Interestingly, Rood-
hart et al. reported platinum-based chemotherapy activatesMSCs
to produce polyunsaturated fatty acids, which confer chemore-
sistance on tumor cells (Roodhart et al., 2011). This gives a
warning in practical settings of treating cancer patients with
chemotherapeutics.
In addition to such epigenetic mutations in tumor cells, spon-
taneous hybridization between tumor cells and MSCs has been
recently demonstrated as a non-mutational mechanism in breast
cancer (Rappa et al., 2012) and lung cancer (Xu et al., 2014).
The tumor/MSC-fused cells have CSC-like properties such as
high tumorigenicity and metastaticity, maintaining both profiles
of tumor cells and MSCs. In our study, when tumor cells were
cocultured with the sMSCs in phagocytosis assay, a few tumor
cells were engulfed by the sMSCs, but not fused together, and the
tumor cells taken were kept inside of the sMSCs alive without
cell death or digestion for a long term (unpublished data). This
may be another mechanism that tumor cells lurk with the help of
MSCs in the host. To analyze the phenotype and behavior of these
tumor-holdingMSCsmay contribute to further understanding of
the mechanism involved in tumor survival and escape. Interest-
ingly, it has been also demonstrated that MSCs transform into
tumor-like cells with high proliferative ability following sponta-
neous mutations (Miura et al., 2006; Tolar et al., 2007; Rosland
et al., 2009; Mohseny and Hogendoorn, 2011). This seems to be
the fundamental mechanism underlying the emergence of the
cancer stem cells originated from non-cancerous cells in the host.
MSCs Protect Tumor Cells from Immune
Attack
MSCs cause immune suppression and dysfunction, which totally
support all steps of tumor progression (Nauta and Fibbe, 2007;
Uccelli et al., 2008). Such immunoregulatory MSCs have been
interest in the therapy to properly induce and activate anti-tumor
immune responses in cancer patients, since impaired immu-
nity has been a critical issue in the treatment (Uccelli et al.,
2008; Yang et al., 2013). Recent studies have demonstrated that
MSCs become immunosuppressive following activation through
inflammatory signals (Burr et al., 2013; English, 2013). A tumor
tissue, where is a milieu filled with abundant pro-inflammatory
molecules produced by tumor cells and a variety of the infiltrat-
ing cells, could be the best educational place for MSCs to acquire
the distinctive competence to support tumor cells. However, how
to distinguish between the cancer-activated MSCs and normal
healthy MSCs remains to be elucidated.
In our study, we identified CCL2, CCL3, and FSTL1 as the
prominent immunomodulatory molecules upregulated only in
the sMSCs. The sMSCs generate functionally impaired CD8low
T cells through cell-cell contact with ALCAM expressed on the
sMSCs (Kudo-Saito et al., 2013a), in addition to regular Tregs
as reported elsewhere (Nauta and Fibbe, 2007; Uccelli et al.,
2008; Maggini et al., 2010). In the previous studies showing
Treg or CD8low T-cell induction by MSCs, CD8 reduction in
the Foxp3+ T cells (Prevosto et al., 2007), or Foxp3 expres-
sion in the CD8low T cells (Giuliani et al., 2011) were not ana-
lyzed. The sMSC-derived FSTL1 might amplify such abnormal
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immunity by promoting the sMSC expansion in an autocrine
manner as well as a paracrine manner by the metastatic tumor-
derived FSTL1. CCL2 is also responsible for immunosuppression.
In our study, CCL2 orchestrates CCR2-expressing immunomod-
ulatory cells including Tregs, MDSCs and TAMs in the tumor
microenvironment, and generates DCregs partly in collaboration
with LCN2 that is released from the CCL2-stimulated tumor cells
(Kudo-Saito et al., 2013b). Tregs within tumor microenviron-
ment have been demonstrated to highly express a CCL3 receptor,
CCR5 (Tan et al., 2009; Schlecker et al., 2012). The sMSC-derived
CCL3 may also help to promptly create a beneficial environ-
ment for immunoevasion of tumor cells by recruiting the cancer-
associated CCR5+ Tregs, although not yet investigated in our
study.
Concluding Remarks
The significant advances in profiling MSCs provided abun-
dant knowledge about MSCs, and revealed the central role of
MSCs in tumor development and progression. The emerging
evidences show that MSCs stand out as a promising thera-
peutic target for treating cancer and the consequent impaired
immunity in patients. Nevertheless, we have understood little
about the MSCs interacting with tumor cells in the in vivo
setting. Our sMSC study is gradually unmasking the character-
istics of the cancer-activated MSCs that can sharply build hetero-
geneic and complexed microenvironment beneficial for tumor
survival and escape in the host. However, further studies are
still needed to achieve translation of the findings to the clinical
therapy.
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